Abstract Library

#4044 18 F-DOPA PET/CT leading to diagnosis of micro pheochromocytoma

Introduction: Pheochromocytomas are rare neuroendocrine tumors arising from the chromaffin cells of the adrenal medulla. The recent revision in the WHO classification of Endocrine Tumors 2022 has replaced the historical term "nodular hyperplasia" with "micro pheochromocytoma," owing to the presence of similar molecular clonal changes as larger tumors.

Conference:

Presenting Author:

Authors: Roman-Gonzalez A, Arias L, Castellano A, Toro J, Vega I,

Keywords: Pheochromocytoma, PET-CT, Paraganglioma, NGS,

#1532 Epidemiology, Pathological Features and Clinical Outcome of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)

Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs coordinated by the scientific multidisciplinary Spanish society GETNE, that covers 57 academic and community sites representing all regions of Spain.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Jimenez-Fonseca P, Capdevila J, Alonso Orduña V, Fernández Medina I, Teule Vega A,

Keywords: Neuroendocrine tumor, registry, Spain, survival,

#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)

Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nuñez B

Authors: Nuñez B, Castaño A, Teule Vega A, Marazuela Azpíroz M, Medina K,

Keywords: NET, surgery, somatostatin analogues, chemotherapy, targeted therapy, survival,

#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy

Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Teulé Vega A, Ochoa M, Villabona C, Cuadra C, Salazar Soler R,

Keywords: pancreatic neuroendocrine tumor, everolimus, octreotide LAR, case study,